PMA device
Proclaim SCS Neurostimulator System
Abbott Medical · Dorsal Root Ganglion Stimulator For Pain Relief (PMP, Class III) · First FDA decision Jan 19, 2021, newest Jan 19, 2021Chronic pain
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
7
Naming "Proclaim SCS"
MAUDE reports
14
Brand "Proclaim SCS", since 2015
PubMed studies
0
Mentioning "Proclaim SCS"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Proclaim SCS Neurostimulator System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Proclaim SCS Neurostimulator SystemPMA supplement
P150004-S041 · Decided Jan 19, 2021 · 189 days after receipt · Normal 180 Day Track
Device type: Dorsal root ganglion stimulator for pain relief (PMP) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Proclaim SCS", any status and sponsor, newest update first.
- Efficacy and Feasibility of BurstDR SCS in Painful Diabetic NeuropathyEnrolling by invitation
TriCity Research CenterNot on our public-company list
NCT07250828 · 20 participants (planned) · Start Dec 15, 2025 · Primary completion Jan 2027
Device: BurstDR Spinal Cord Stimulation · For: Painful Diabetic Neuropathy (PDN); Diabetic Neuropathy; Neuropathic Pain and 1 more
Sites: Grand Island, Nebraska
Nora VanegasAcademic, hospital or other
NCT03526991 · 10 participants · Start Aug 1, 2021 · Primary completion Feb 28, 2026
Device: Spinal Cord Stimulator (SCS) · For: Parkinson Disease
Sites: New York, New York; Houston, Texas
- Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)Pivotal-lookingCompleted
Abbott Medical DevicesPublic (ABT)
NCT04479787 · 270 participants · Start Jul 31, 2020 · Primary completion Aug 23, 2022
Device: Spinal Cord Stimulation · For: Chronic Low-Back Pain; Refractory Pain; Neuropathic Pain
Sites: Phoenix, Arizona; Tucson, Arizona; Camarillo, California · 30 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Proclaim SCS", and for the whole product code for context.
This brand
14 reports: 2 malfunction, 12 injury, 0 death
Whole product code PMP
20,258 reports: 250 malfunction, 19,968 injury, 32 death
Newest reports for this brand
- PROCLAIM SCSInjury
MW5187491 · Received Apr 30, 2026
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Patient problem as coded: Inadequate Pain Relief
- PROCLAIM SCSInjury
MW5153922 · Received Apr 16, 2024
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Patient problem as coded: Pain
- PROCLAIM SCS SYSTEMInjury
MW5147978 · Received Nov 8, 2023
Device type: Stimulator, Spinal-Cord, Totally Implanted For Pain Relief (LGW)
Patient problem as coded: Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Proclaim SCS"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PMP.
- Axium Neurostimulator SystemAbbott Medical · PMA 2024
- Proclaim DRG IPG (Model 3664)Abbott Medical · PMA 2023
- Proclaim Dorsal Root Ganglion (DRG) Neurostimulator SystemAbbott Medical · PMA 2026
- Dorsal Root Ganglion (DRG) Neurostimulation SystemAbbott Medical · PMA 2025
- SlimTip Dorsal Root Ganglion (DRG) Trial Lead KitAbbott Medical · PMA 2025
- Family of DRG IPGsAbbott Medical · PMA 2024
- NextGen DRG Lead Kit and AccessoriesAbbott Medical · PMA 2021
- PmpAbbott Medical · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.